Plant-based products that do not contain meat can continue to be labeled “sausages” or “burgers,” European lawmakers said Friday, when they rejected a proposal back by the meat industry to ban the terms.

In votes on issues relating to agricultural products, the European Parliament said that so-called veggie burgers, soy steaks and vegan sausages can continue to be sold as such in restaurants and shops across the union.

Europe’s largest farmers' association, Copa-Cogeca, had supported a ban, arguing that labeling vegetarian substitutes with designations bringing meat to mind was misleading for consumers.

On the opposite side of the debate, a group of 13 organizations including Greenpeace and WWF urged lawmakers to reject the proposed amendments, arguing that a ban would have not only exposed the EU “to ridicule," but also damaged its environmental credibility.

They said promoting a shift toward more plant-based diet is in line with the EU Commission's ambition to tackle global warming. Losing the ability to use the terms steak or sausage might make those plant-based products more obscure for consumers.

After the vote, the European Consumer Organization, an umbrella group bringing together consumers' associations, praised the MEPs for their “common sense."

“Consumers are in no way confused by a soy steak or chickpea-based sausage, so long as it is clearly labeled as vegetarian or vegan," the group said in a statement. “Terms such as ‘burger’ or ‘steak’ on plant-based items simply make it much easier for consumers to know how to integrate these products within a meal."

Together with Greenpeace, the group regretted that lawmakers accepted further restrictions on the naming of alternative products containing no dairy. Terms like ‘almond milk’ and ‘soy yogurt’ are already banned in Europe after the bloc's top court ruled in 2017 that purely plant-based products can't be marketed using terms such as milk, butter or cheese, which are reserved for animal products.

Share:
More In Business
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More